170 related articles for article (PubMed ID: 28528206)
1. Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.
Li N; Noticewala SS; Williamson CW; Shen H; Sirak I; Tarnawski R; Mahantshetty U; Hoh CK; Moore KL; Mell LK
Radiother Oncol; 2017 May; 123(2):325-330. PubMed ID: 28528206
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
3. A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial.
Yusufaly T; Miller A; Medina-Palomo A; Williamson CW; Nguyen H; Lowenstein J; Leath CA; Xiao Y; Moore KL; Moxley KM; Chevere-Mourino CM; Eng TY; Zaid T; Mell LK
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1240-1247. PubMed ID: 32629079
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging.
Qin X; Gong G; Wang L; Su Y; Yin Y
Radiat Oncol; 2022 Dec; 17(1):207. PubMed ID: 36517839
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
6. Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer.
Bao Z; Wang D; Chen S; Chen M; Jiang D; Yang C; Liu H; Dai J; Xie C
Radiat Oncol; 2019 Aug; 14(1):118. PubMed ID: 31378200
[TBL] [Abstract][Full Text] [Related]
7. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy.
McGuire SM; Menda Y; Ponto LL; Gross B; Juweid M; Bayouth JE
Radiother Oncol; 2011 Apr; 99(1):49-54. PubMed ID: 21397965
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analysis of VMAT and IMRT Techniques: Evaluation of Dose Constraints and Bone Marrow Sparing in Cervical Cancer Patients Undergoing Chemoradiotherapy.
Thakur N; Kaur H; Kaur S; Lehal P; Sudan M; Jain N; Sharma R; Sharma A
Asian Pac J Cancer Prev; 2024 Jan; 25(1):139-144. PubMed ID: 38285777
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients.
Wyss JC; Carmona R; Karunamuni RA; Pritz J; Hoh CK; Mell LK
Radiother Oncol; 2016 Jan; 118(1):72-8. PubMed ID: 26674924
[TBL] [Abstract][Full Text] [Related]
10. Intensity modulated arc therapy implementation in a three phase adaptive (18)F-FDG-PET voxel intensity-based planning strategy for head-and-neck cancer.
Berwouts D; Olteanu LA; Speleers B; Duprez F; Madani I; Vercauteren T; De Neve W; De Gersem W
Radiat Oncol; 2016 Apr; 11():52. PubMed ID: 27039294
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer.
Song WY; Huh SN; Liang Y; White G; Nichols RC; Watkins WT; Mundt AJ; Mell LK
J Appl Clin Med Phys; 2010 Aug; 11(4):3255. PubMed ID: 21081882
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer.
Murakami N; Okamoto H; Kasamatsu T; Kobayashi K; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Sumi M; Toita T; Ito Y; Itami J
Anticancer Res; 2014 Sep; 34(9):5091-8. PubMed ID: 25202097
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
14. Incorporating
Franco P; Fiandra C; Arcadipane F; Trino E; Giglioli FR; Ragona R; Ricardi U
BMC Cancer; 2017 Nov; 17(1):710. PubMed ID: 29096619
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of bone marrow sparing volumetric modulated arc therapy to spare active bone marrow in cervical and vaginal cancer patients: a retrospective dosimetric analysis.
Beavan M; Dundas K; Hudson F; Surjan Y; Lau A; Deshpande S; Lim K; Do V
J Med Radiat Sci; 2021 Dec; 68(4):379-388. PubMed ID: 34288534
[TBL] [Abstract][Full Text] [Related]
16. Highly Efficient Training, Refinement, and Validation of a Knowledge-based Planning Quality-Control System for Radiation Therapy Clinical Trials.
Li N; Carmona R; Sirak I; Kasaova L; Followill D; Michalski J; Bosch W; Straube W; Mell LK; Moore KL
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):164-172. PubMed ID: 27979445
[TBL] [Abstract][Full Text] [Related]
17. A dosimetric analysis of tomotherapy based intensity modulated radiation therapy with and without bone marrow sparing in gynecologic malignancies.
Platta CS; Bayliss A; McHaffie D; Tome WA; Straub MR; Bradley KA
Technol Cancer Res Treat; 2013 Feb; 12(1):19-29. PubMed ID: 22974331
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients.
Deng X; Han C; Chen S; Xie C; Yi J; Zhou Y; Zheng X; Deng Z; Jin X
J Appl Clin Med Phys; 2017 Jan; 18(1):25-31. PubMed ID: 28291936
[TBL] [Abstract][Full Text] [Related]
20. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
